CytomX Announces Global Strategic Collaboration with Pfizer
Friday, June 07, 2013
CytomX eligible to receive approximately $25 million in upfront, research reimbursement and preclinical milestone payments, $610 million in regulatory and sales milestones, plus tiered royalties on sales.

CovalX and Bruker Daltonics Announce Strategic Collaboration
Thursday, June 06, 2013
The agreement aims to advance protein research in the area of protein interactions and macromolecular characterization by supporting the combination of the two company’s technologies.

NIH to Fund Clinical Research Network on Antibacterial Resistance
Thursday, June 06, 2013
Researchers at Duke University will lead the initiative.

Combined Immunotherapy Shows Promising Results Against Advanced Melanoma
Wednesday, June 05, 2013
Tumor regression rates are produced by combining two cancer immunotherapy drugs.

NANOBIOTIX Announced Positive Phase I Results of NBTXR3
Tuesday, June 04, 2013
Company’s NBTXR3 achieves clinical milestone reaching proof-of-concept in phase I trial of STS.

MorphoSys Signs Global License Agreement with GSK
Tuesday, June 04, 2013
MorphoSys to receive committed and success-based payments of up to EUR 445 million and double-digit royalties on net sales.

Promising Drug Prevents Cancer Cells from Shutting Down Immune System
Tuesday, June 04, 2013
Data from Phase 1 trial presented at the 2013 annual meeting of the ASCO in Chicago.

MorphoSys Signs Global License Agreement with GSK for Anti-Inflammatory Program
Tuesday, June 04, 2013
MorphoSys to receive committed and success-based payments of up to €445 million and double-digit royalties on net sales.

<<	1 2 3 4 5 6 7	>>
Showing Results 31 - 40 of 2323